Albano, D., Dondi, F., Bertagna, F., & Treglia, G. (2022). The Role of [68Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review. Cancers, 14(15), 3814. https://doi.org/10.3390/cancers14153814

Buck, A. K., Stolzenburg, A., Hänscheid, H., Schirbel, A., Lückerath, K., Schottelius, M., Wester, H.-J., & Lapa, C. (2017). Chemokine receptor—Directed imaging and therapy. Methods (San Diego, Calif.), 130, 63–71. https://doi.org/10.1016/j.ymeth.2017.09.002

Eiber, M., Kratochwil, C., Lapa, C., & Brenner, W. (2021). Nuklearmedizinische Theranostik. Der Onkologe. https://doi.org/10.1007/s00761-021-00956-1

Hadebe, B., Sathekge, M. M., Aldous, C., & Vorster, M. (2022). Current Status of 68Ga-Pentixafor in Solid Tumours. Diagnostics, 12(9), 2135. https://doi.org/10.3390/diagnostics12092135

Herrmann, K., Schwaiger, M., Lewis, J. S., Solomon, S. B., McNeil, B. J., Baumann, M., Gambhir, S. S., Hricak, H., & Weissleder, R. (2020). Radiotheranostics: A roadmap for future development. The Lancet Oncology, 21(3), e146–e156. https://doi.org/10.1016/S1470-2045(19)30821-6

Jamet, B., Bailly, C., Carlier, T., Touzeau, C., Nanni, C., Zamagni, E., Barré, L., Michaud, A.-V., Chérel, M., Moreau, P., Bodet-Milin, C., & Kraeber-Bodéré, F. (2019). Interest of Pet Imaging in Multiple Myeloma. Frontiers in Medicine, 6, 69. https://doi.org/10.3389/fmed.2019.00069

Kircher, M., Herhaus, P., Schottelius, M., Buck, A. K., Werner, R. A., Wester, H.-J., Keller, U., & Lapa, C. (2018). CXCR4-directed theranostics in oncology and inflammation. Annals of Nuclear Medicine, 32(8), 503–511. https://doi.org/10.1007/s12149-018-1290-8

Man, F., Gawne, P. J., & T.M. de Rosales, R. (2019). Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine. Advanced Drug Delivery Reviews, 143, 134–160. https://doi.org/10.1016/j.addr.2019.05.012

Mayerhoefer, M. E., Archibald, S. J., Messiou, C., Staudenherz, A., Berzaczy, D., & Schöder, H. (2020). MRI and PET/MRI in hematologic malignancies. Journal of Magnetic Resonance Imaging, 51(5), 1325–1335. https://doi.org/10.1002/jmri.26848

Mesguich, C., Zanotti-Fregonara, P., & Hindié, E. (2016). New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. Theranostics, 6(2), 287–290. https://doi.org/10.7150/thno.14400

Narula, J., Dilsizian, V., & Chandrashekhar, Y. (2015). Molecular Imaging: From Deep Pearl Diving to Enlightenment. JACC. Cardiovascular Imaging, 8(12), 1472–1474. https://doi.org/10.1016/j.jcmg.2015.11.004

Pandit-Taskar, N. (2018). Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods. Seminars in Hematology, 55(1), 22–32. https://doi.org/10.1053/j.seminhematol.2018.02.009

Schottelius, M., Herrmann, K., & Lapa, C. (2021). In Vivo Targeting of CXCR4-New Horizons. Cancers, 13(23), Article 23. https://doi.org/10.3390/cancers13235920

Toczek, J., & Riou, L. (2020). Considerations on PET/MR imaging of carotid plaque inflammation with 68Ga-Pentixafor. Journal of Nuclear Cardiology. https://doi.org/10.1007/s12350-020-02354-3

Walenkamp, A. M. E., Lapa, C., Herrmann, K., & Wester, H.-J. (2017). CXCR4 Ligands: The Next Big Hit? Journal of Nuclear Medicine, 58(Supplement 2), 77S-82S. https://doi.org/10.2967/jnumed.116.186874